Skip to main content
Fig. 1 | World Journal of Surgical Oncology

Fig. 1

From: Proline-rich protein 11 overexpression is associated with a more aggressive phenotype and poor overall survival in ovarian cancer patients

Fig. 1

PRR11 expression in human ovarian cancer (OC) and non-cancerous tissues. A-1 Negative staining of PRR11 in the epithelium of ovarian benign lesions. A-2, A-3 Low expression of PRR11 in poorly-differentiated cancer cells. A-4 High expression of PRR11 in endometrioid adenocarcinoma. A-5 Strong staining of PRR11 in the front edge of serous carcinoma. A-6 Negative staining of PRR11 in serous carcinoma. The original magnification is 200×. b Graphical representation of the intensity of PRR11 staining in cancer tumors and noncancerous tissues. c Expression of PRR11 in benign lesions, intraepithelial neoplasm (IEN), tumor at stages I/II, tumor at stages III/IV, and intravascular tumor emboli. d The intensity of the PRR11 staining increases with the progression of OC: 0.115 ± 0.29 in benign lesions, 0.32 ± 0.39 in intraepithelial neoplasm (IEN), 0.51 ± 0.60 in tumors at stages I/II, 0.62 ± 0.63 in tumors at stage III/IV, and 3-0.29 in intravascular tumor emboli. *P < 0.05, ***P < 0.001. e Gene expression omnibus (GEO) repository dataset (the data from GDS3592 data set) profiles revealed higher expression of PRR11 in OC epithelial cells than the expression observed in ovarian normal surface epithelia. *P < 0.05, ***P < 0.001

Back to article page